Literature DB >> 17627863

A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia.

A McKinlay1, R C Grace, J C Dalrymple-Alford, T Anderson, J Fink, D Roger.   

Abstract

Neuropsychiatric problems are common in Parkinson's disease (PD) but there is little information regarding how they impact on quality of life. PD patients without dementia (49) were assessed for low mood/depression, fatigue, apathy, sleep problems and hallucinations. Measures of quality of life and motor function were also obtained. Over 77% of the patients reported symptoms consistent with one or more neuropsychiatric problems. Low mood/depression, anxiety and the presence of hallucinations predicted poorer quality of life after controlling for motor symptoms. Additional to the motor symptoms, we found that specific neuropsychiatric problems may impact on quality of life for PD patients.

Entities:  

Mesh:

Year:  2007        PMID: 17627863     DOI: 10.1016/j.parkreldis.2007.05.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  48 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 3.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

4.  Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer's disease to Parkinson's disease.

Authors:  Hongyoon Choi; Yu Kyeong Kim; Eun Jin Yoon; Jee-Young Lee; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-25       Impact factor: 9.236

5.  Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease.

Authors:  Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne A Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Peter V Rabins; Howard D Weiss; Laura Marsh
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

6.  Plasma levels of miR-137 and miR-124 are associated with Parkinson's disease but not with Parkinson's disease with depression.

Authors:  Na Li; Xudong Pan; Jingli Zhang; Aijun Ma; Shaonan Yang; Juanjuan Ma; Anmu Xie
Journal:  Neurol Sci       Date:  2017-02-08       Impact factor: 3.307

7.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

8.  Association between antidepressants and falls in Parkinson's disease.

Authors:  Daniel Martinez-Ramirez; Juan C Giugni; Leonardo Almeida; Roger Walz; Bilal Ahmed; Fiona A Chai; Valerie Rundle-Gonzalez; Alberto R Bona; Erin Monari; Aparna Wagle Shukla; Christopher W Hess; Chris J Hass; Michael S Okun
Journal:  J Neurol       Date:  2015-10-29       Impact factor: 4.849

9.  Facial emotion recognition impairment in patients with Parkinson's disease and isolated apathy.

Authors:  Mercè Martínez-Corral; Javier Pagonabarraga; Gisela Llebaria; Berta Pascual-Sedano; Carmen García-Sánchez; Alexandre Gironell; Jaime Kulisevsky
Journal:  Parkinsons Dis       Date:  2010-07-28

Review 10.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.